The Lancet

When to and when not to use machine learning in risk prediction models

Machine learning for health data science, fuelled by proliferation of data and reduced computational costs, has garnered ...
ascopubs.org

Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in ...
Open Heart

Enhanced cardiovascular disease risk prediction using integrated machine learning models: a study from the UK Biobank cohort

Objective Cardiovascular diseases (CVD) remain the leading cause of mortality globally, necessitating early risk ...
ascopubs.org

Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care

Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling Participants with stage I-III breast cancer were prospectively included from CANTO (ClinicalTrials.gov ...